Search

Your search keyword '"Zijlstra, Eric"' showing total 159 results
Start Over Author "Zijlstra, Eric"
159 results on '"Zijlstra, Eric"'

8. Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion

Author

Leohr, Jennifer, primary, Dellva, Mary Anne, additional, LaBell, Elizabeth, additional, Coutant, David E., additional, Arrubla, Jorge, additional, Plum‐Mörschel, Leona, additional, Zijlstra, Eric, additional, Fukuda, Tsuyoshi, additional, and Hardy, Thomas, additional

Published
2023
Full Text
View/download PDF

9. Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusion.

Author

Leohr, Jennifer, Dellva, Mary Anne, LaBell, Elizabeth, Coutant, David E., Arrubla, Jorge, Plum‐Mörschel, Leona, Zijlstra, Eric, Fukuda, Tsuyoshi, and Hardy, Thomas

Subjects
TYPE 1 diabetes, SUBCUTANEOUS infusions, HYPERGLYCEMIA, BOLUS drug administration, BLOOD sugar, CINNAMON
Abstract

Aims: To compare the time to hyperglycaemia recovery after ultra rapid lispro (URLi; Lyumjev®) versus Humalog in a randomized, double‐blind crossover study. Materials and Methods: Thirty‐two adults with type 1 diabetes on continuous subcutaneous insulin infusion participated in two periods: each period included hyperglycaemia induced by a missed mealtime bolus (day 1) and by suspension of basal insulin delivery (day 2). When hyperglycaemia [plasma glucose (PG) >240 mg/dl] occurred, a correction bolus of URLi or Humalog was given and time to hyperglycaemia recovery (PG = 140 mg/dl), pharmacokinetics and glucodynamics were compared. Results: Following a missed mealtime bolus, URLi significantly reduced maximum PG (−13 mg/dl; p =.02), and produced numerically more rapid decline in PG (23 mg/dl/h; p =.07), and faster recovery from hyperglycaemia (−23 min; p =.1) versus Humalog, although differences were not significant. Following basal suspension, URLi significantly reduced maximum PG (−6 mg/dl; p =.02), and produced faster PG decline (24 mg/dl/h; p <.001) and faster recovery from hyperglycaemia (−16 min; p <.01) vs. Humalog. Following a correction bolus of URLi, accelerated insulin lispro absorption was observed versus Humalog: early 50% tmax was reduced by 6 or 12 min, and AUC0‐15min was increased 2.5‐ or 4.3‐fold after correction boluses by subcutaneous infusion (day 1) or injection (day 2), respectively (all p <.001). Conclusions: During episodes of hyperglycaemia commonly experienced in people with type 1 diabetes, URLi provided a faster recovery versus Humalog from a missed mealtime bolus or during basal insulin suspension. URLi shows significant acceleration of insulin absorption versus Humalog when boluses are administered by subcutaneous infusion or injection. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU‐ und US‐sourced reference insulins.

Author

Chen, Wei, Lu, Jia, Plum‐Mörschel, Leona, Andersen, Grit, Zijlstra, Eric, He, Anshun, Xie, Tian, Li, Longling, Hao, Chunyue, Gan, Zhongru, and Heise, Tim

Subjects
INSULIN aspart, GENERIC drugs, INSULIN, PHARMACOKINETICS, TYPE 1 diabetes, INSULIN therapy, GLUCOSE clamp technique
Abstract

Aim: For the successful approval and clinical prescription of insulin biosimilars, it is essential to show pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to the respective reference products sourced from the European Union and the United States. Methods: Three phase 1, randomized, double‐blind, three‐period crossover trials compared single doses of the proposed biosimilar insulin analogues aspart (GL‐Asp, n = 36), lispro (GL‐Lis, n = 38) and glargine (GL‐Gla, n = 113), all manufactured by Gan & Lee pharmaceuticals, to the respective EU‐ and US‐reference products in healthy male participants (GL‐Asp and GL‐Lis) or people with type 1 diabetes (GL‐Gla). Study participants received 0.2 U/kg (aspart and lispro) or 0.5 U/kg (glargine) of each treatment under automated euglycaemic clamp conditions. The clamp duration was 12 h (aspart and lispro) or 30 h (glargine). Primary PK endpoints were the total area under the PK curves (AUCins.total) and maximum insulin concentrations (Cins.max). Primary PD endpoints were the total area under the glucose infusion rate curve (AUCGIR.total) and maximum glucose infusion rate (GIRmax). Results: Bioequivalence to both EU‐ and US‐reference products were shown for all three GL insulins. Least squares mean ratios for the primary PK/PD endpoints were close to 100%, and both 90% and 95% confidence intervals were within 80%–125% in all three studies. There were no noticeable differences in the safety profiles between test and reference insulins, and no serious adverse events were reported for the GL insulins. Conclusion: GL‐Asp, GL‐Lis and GL‐Gla are bioequivalent to their EU‐ and US‐reference products. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. sj-docx-1-dst-10.1177_19322968231170242 – Supplemental material for Noninvasive Continuous Glucose Monitoring With a Novel Wearable Dial Resonating Sensor: A Clinical Proof-of-Concept Study

Author

Handy, Consuelo, Chaudhry, Mohamed Sabih, Qureshi, Muhammad Rafaqat Ali, Love, Bradley, Shillingford, John, Plum-Mörschel, Leona, and Zijlstra, Eric

Subjects
111708 Health and Community Services, FOS: Clinical medicine, 111199 Nutrition and Dietetics not elsewhere classified, Medicine, FOS: Health sciences, 110306 Endocrinology
Abstract

Supplemental material, sj-docx-1-dst-10.1177_19322968231170242 for Noninvasive Continuous Glucose Monitoring With a Novel Wearable Dial Resonating Sensor: A Clinical Proof-of-Concept Study by Consuelo Handy, Mohamed Sabih Chaudhry, Muhammad Rafaqat Ali Qureshi, Bradley Love, John Shillingford, Leona Plum-Mörschel and Eric Zijlstra in Journal of Diabetes Science and Technology

Published
2023
Full Text
View/download PDF

15. sj-docx-1-dst-10.1177_19322968221145200 – Supplemental material for Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes

Author

Garhyan, Parag, Pratt, Edward, Klein, Oliver, Famulla, Susanne, Zijlstra, Eric, Lalonde, Amy, Swinney, Monica, Kazda, Christof, and Dassau, Eyal

Subjects
111708 Health and Community Services, FOS: Clinical medicine, 111199 Nutrition and Dietetics not elsewhere classified, Medicine, FOS: Health sciences, 110306 Endocrinology
Abstract

Supplemental material, sj-docx-1-dst-10.1177_19322968221145200 for Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes by Parag Garhyan, Edward Pratt, Oliver Klein, Susanne Famulla, Eric Zijlstra, Amy Lalonde, Monica Swinney, Christof Kazda and Eyal Dassau in Journal of Diabetes Science and Technology

Published
2023
Full Text
View/download PDF

21. Faster Recovery from Hyperglycemia with Ultra Rapid Lispro (URLi) vs Insulin Lispro in Patients with Type 1 Diabetes (T1D) on Continuous Subcutaneous Insulin Infusion (CSII)

Author

Leohr, Jennifer, additional, Dellva, Mary Anne, additional, LaBell, Elizabeth, additional, Tong, Zhentao, additional, Arrubla, Jorge, additional, Plum-Mörschel, Leona, additional, Zijlstra, Eric, additional, Fukuda, Tsuyoshi, additional, Hardy, Thomas, additional, and Gehr, Bernhard, additional

Published
2022
Full Text
View/download PDF

28. Differences in physiological responses to cardio-pulmonary exercise testing in adults with type 1 diabetes and controls without type 1 diabetes – a pooled analysis

Author

Eckstein, Max L., primary, Farinha, Juliano Boufleur, primary, McCarthy, Olivia, primary, West, Daniel J., primary, Yardley, Jane E., primary, Bally, Lia, primary, Zueger, Thomas, primary, Stettler, Christoph, primary, Boff, Winston, primary, Reischak-Oliveira, Alvaro, primary, Riddell, Michael C., primary, Zaharieva, Dessi P., primary, Pieber, Thomas R., primary, Müller, Alexander, primary, Birnbaumer, Philipp, primary, Aziz, Faisal, primary, Brugnara, Laura, primary, Haahr, Hanne, primary, Zijlstra, Eric, primary, Heise, Tim, primary, Sourij, Harald, primary, Roden, Michael, primary, Hofmann, Peter, primary, Bracken, Richard M., primary, Pesta, Dominik, primary, and Moser, Othmar, primary

Published
2020
Full Text
View/download PDF

29. Differences in Physiological Responses to Cardiopulmonary Exercise Testing in Adults With and Without Type 1 Diabetes: A Pooled Analysis

Author

Eckstein, Max L., primary, Farinha, Juliano Boufleur, additional, McCarthy, Olivia, additional, West, Daniel J., additional, Yardley, Jane E., additional, Bally, Lia, additional, Zueger, Thomas, additional, Stettler, Christoph, additional, Boff, Winston, additional, Reischak-Oliveira, Alvaro, additional, Riddell, Michael C., additional, Zaharieva, Dessi P., additional, Pieber, Thomas R., additional, Müller, Alexander, additional, Birnbaumer, Philipp, additional, Aziz, Faisal, additional, Brugnara, Laura, additional, Haahr, Hanne, additional, Zijlstra, Eric, additional, Heise, Tim, additional, Sourij, Harald, additional, Roden, Michael, additional, Hofmann, Peter, additional, Bracken, Richard M., additional, Pesta, Dominik, additional, and Moser, Othmar, additional

Published
2020
Full Text
View/download PDF

31. Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study

Author

Heise, Tim, primary, Linnebjerg, Helle, additional, Coutant, David, additional, LaBell, Elizabeth, additional, Zijlstra, Eric, additional, Kapitza, Christoph, additional, Bue‐Valleskey, Juliana, additional, Zhang, Qianyi, additional, Dellva, Mary Anne, additional, and Leohr, Jennifer, additional

Published
2020
Full Text
View/download PDF

32. 1019-P: Variability of 501 Inhaled Insulin Absorption and Action

Author

ZIJLSTRA, ERIC, primary, ANDERSEN, GRIT, additional, PLUM-MOERSCHEL, LEONA, additional, RHODES, MELISSA, additional, PATTON, RYAN, additional, BUECHE, BLAINE, additional, KUO, MEI-CHANG, additional, LE, TRUC H., additional, STEDMAN, BENJAMIN J., additional, and PATTON, JOHN S., additional

Published
2020
Full Text
View/download PDF

34. 96 - Ultra Rapid Lispro (URLi) Lowers Postprandial Glucose (PPG) and More Closely Matches Normal Physiological Glucose Response Compared to Other Rapid Insulin Analogs

Author

Heise, Tim, primary, Linnebjerg, Helle, additional, Cao, Dachuang, additional, Coutant, David E., additional, Labell, Elizabeth S., additional, Reddy, Shobha R., additional, Bowerman, Sabina, additional, Zijlstra, Eric, additional, Kapitza, Christoph, additional, Bue-Valleskey, Juliana M., additional, Zhang, Qianyi, additional, and Leohr, Jennifer K., additional

Published
2019
Full Text
View/download PDF

35. 150-OR: BioChaperone Pramlintide Insulin (BCPramIns), a New Co-Formulation of Pramlintide (PRAM) and Human Insulin (INS), Improves Postprandial Blood Glucose (BG) vs. Both Separate Injections of PRAM+INS and Insulin Lispro (LIS) in Subjects with T1D

Author

MEIFFREN, GRÉGORY, primary, SEROUSSI, CYRIL, additional, RANSON, AYMERIC, additional, CHARVET, RICHARD, additional, GAUDIER, MARTIN, additional, ANDERSEN, GRIT, additional, ZIJLSTRA, ERIC, additional, DEVRIES, J. HANS, additional, HEISE, TIM, additional, SOULA, RÉMI, additional, and SOULA, OLIVIER, additional

Published
2019
Full Text
View/download PDF

37. 1100-P: Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs. Humalog (Lispro) in Patients with T2D

Author

LEOHR, JENNIFER, primary, DELLVA, MARY A., additional, COUTANT, DAVID E., additional, LABELL, ELIZABETH S., additional, REDDY, SHOBHA, additional, HEISE, TIM, additional, ANDERSEN, GRIT, additional, ZIJLSTRA, ERIC, additional, HERMANSKI, LIDIA, additional, NOSEK, LESZEK, additional, and LINNEBJERG, HELLE, additional

Published
2019
Full Text
View/download PDF

38. Differences in Physiological Responses to Cardiopulmonary Exercise Testing in Adults With and Without Type 1 Diabetes: A Pooled Analysis.

Author

Eckstein, Max L., Farinha, Juliano Boufleur, McCarthy, Olivia, West, Daniel J., Yardley, Jane E., Bally, Lia, Zueger, Thomas, Stettler, Christoph, Boff, Winston, Reischak-Oliveira, Alvaro, Riddell, Michael C., Zaharieva, Dessi P., Pieber, Thomas R., Müller, Alexander, Birnbaumer, Philipp, Aziz, Faisal, Brugnara, Laura, Haahr, Hanne, Zijlstra, Eric, and Heise, Tim

Subjects
TYPE 1 diabetes, EXERCISE tests, PRE-tests & post-tests, HEART beat, EXERCISE, RESEARCH, EXERCISE tolerance, OXYGEN consumption, RESEARCH methodology, MEDICAL cooperation, EVALUATION research, COMPARATIVE studies
Abstract

Objective: To investigate physiological responses to cardiopulmonary exercise (CPX) testing in adults with type 1 diabetes compared with age-, sex-, and BMI-matched control participants without type 1 diabetes.Research Design and Methods: We compared results from CPX tests on a cycle ergometer in individuals with type 1 diabetes and control participants without type 1 diabetes. Parameters were peak and threshold variables of VO2, heart rate, and power output. Differences between groups were investigated through restricted maximum likelihood modeling and post hoc tests. Differences between groups were explained by stepwise linear regressions (P < 0.05).Results: Among 303 individuals with type 1 diabetes (age 33 [interquartile range 22; 43] years, 93 females, BMI 23.6 [22; 26] kg/m2, HbA1c 6.9% [6.2; 7.7%] [52 (44; 61) mmol/mol]), VO2peak (32.55 [26.49; 38.72] vs. 42.67 ± 10.44 mL/kg/min), peak heart rate (179 [170; 187] vs. 184 [175; 191] beats/min), and peak power (216 [171; 253] vs. 245 [200; 300] W) were lower compared with 308 control participants without type 1 diabetes (all P < 0.001). Individuals with type 1 diabetes displayed an impaired degree and direction of the heart rate-to-performance curve compared with control participants without type 1 diabetes (0.07 [-0.75; 1.09] vs. 0.66 [-0.28; 1.45]; P < 0.001). None of the exercise physiological responses were associated with HbA1c in individuals with type 1 diabetes.Conclusions: Individuals with type 1 diabetes show altered responses to CPX testing, which cannot be explained by HbA1c. Intriguingly, the participants in our cohort were people with recent-onset type 1 diabetes; heart rate dynamics were altered during CPX testing. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

39. Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study.

Author

Leohr, Jennifer, Dellva, Mary Anne, Coutant, David E., LaBell, Elizabeth, Heise, Tim, Andersen, Grit, Zijlstra, Eric, Hermanski, Lidia, Nosek, Leszek, and Linnebjerg, Helle

Subjects
TYPE 2 diabetes, INSULIN aspart, GLUCOSE clamp technique, BLOOD sugar
Abstract

Background and objective: Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This study compared the insulin lispro pharmacokinetics and glucodynamics, safety and tolerability of URLi and Humalog® after a single subcutaneous dose in patients with type 2 diabetes mellitus (T2DM). Methods: This was a phase I, randomised, two-period, two-treatment, double-blind, crossover study in 38 patients with T2DM. At each dosing visit, patients received either 15 units of URLi or Humalog, followed by a 10 h automated euglycaemic clamp procedure. Serum insulin lispro and blood glucose were measured. Results: Insulin lispro appeared in the serum 5 min faster (p < 0.0001) and exposure was 6.4-fold greater in the first 15 min (p < 0.0001) with URLi versus Humalog. Exposure beyond 3 h postdose was 26% lower and the duration of exposure was 51 min shorter with URLi versus Humalog. Onset of insulin action was 13 min faster (p < 0.0001) and insulin action was 4.2-fold greater within the first 30 min (p < 0.0001) with URLi versus Humalog. Insulin action beyond 4 h postdose was 20% lower (p = 0.0099) with URLi versus Humalog. Overall insulin lispro exposure and total glucose infused were similar for URLi and Humalog. Both treatments were well tolerated. Conclusions: This is the first study to investigate URLi in patients with T2DM using a euglycaemic clamp procedure. URLi demonstrated ultra-rapid pharmacokinetics and glucodynamics in patients with T2DM. ClinicalTrials.gov identifier: NCT03305822. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

42. BioChaperone Glucagon (BCG), a Stable Ready-to-Use Liquid Glucagon Formulation, Is Well Tolerated and Quickly Restores Euglycemia after Insulin-Induced Hypoglycemia

Author

GLEZER, STANISLAV, primary, HOVELMANN, ULRIKE, additional, TENG, SOPHIE, additional, LAMERS, DANIELA, additional, ODOUL, MARION, additional, CORREIA, JOSÉ, additional, ZIJLSTRA, ERIC, additional, GAUDIER, MARTIN, additional, SOULA, OLIVIER, additional, and DURACHER, DAVID, additional

Published
2018
Full Text
View/download PDF

50. Des concentrations en insuline et un effet hypoglycémiant plus élevés et plus précoces avec l’insuline Faster Aspart versus insuline asparte dans des conditions de pratique clinique

Author

Hanaire, Hélène, primary, Heise, Tim, additional, Stender-Petersen, Kristine, additional, Hövelmann, Ulrike, additional, Jacobsen, Jacob Bonde, additional, Nosek, Leszek, additional, Zijlstra, Eric, additional, Haahr, Hanne, additional, and Kessouri, Meriem, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results